IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on...
Cancer
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call...
Tonix Pharmaceuticals to Present at Biotech Showcase 2023
CHATHAM, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will...
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours
Harren Jhoti OBE, PhD, FRS, FMedSci Astex Pharmaceuticals (UK), co-founder and CEO, Harren Jhoti OBE, PhD, FRS, FMedSci next to...
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous...
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage...
Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands...
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands...
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2...
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
Oncotelic Issues Year End Message to Shareholders
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for...
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision...
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO...
DOJ Lawsuit Against Modern Vascular Lacks Merit
Phoenix, Arizona, Dec. 27, 2022 (GLOBE NEWSWIRE) -- After more than two years of investigating Modern Vascular based on qui...
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors...
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that...
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
Initial $3.5M Funding Maintains Cash Runway of Mid-2023SAN DIEGO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a...
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...